Clinical trials: Cervical Squamous Cell Carcinoma, Not Otherwise Specified
Head and Neck Neoplasms
Single Dose Escalation Study of Bivatuzumab Mertansine in Patients With Advanced Squamous Cell Carcinoma of the Head and Neck
maximum tolerated dose (MTD), safety, pharmacokinetics, efficacy of bivatuzumab mertansine
- Trial name
- NCT02254018
- Testing
- bivatuzumab mertansine
- Volunteers
- 31 people
- Sponsor
- Boehringer Ingelheim
Head and Neck Cancer
Studying Biomarkers in Samples From Patients With Recurrent or Metastatic Head and Neck Cancer Treated on E1302 Trial
RATIONALE: Studying samples of blood and tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT01619618
- Testing
- mutation analysis, polymerase chain reaction, polymorphism analysis
- Volunteers
- 183 people
- Sponsor
- Eastern Cooperative Oncology Group
Squamous Cell Carcinoma, Advanced Head and Neck Cancer
Cyclophosphamide and Etoposide as a Metronomic Therapy in Advanced Head and Neck Squamous Cell Cancer
The goal of this clinical trial is to learn if drugs as cyclophosphamide (C) and etoposide (E) work to treat advanced head and neck cancer in adults. It will also learn about the safety of both drugs.
- Trial name
- NCT07361133
- Testing
- Cyclophosphamide and Etoposide in combination, Methotrexate
- Where
- Egypt
- Volunteers
- 120 people
- Sponsor
- National Cancer Institute, Egypt
Esophageal Squamous Cell Carcinoma
Accurate Diagnosis of the Invasion Depth in ESCC by a Deep Neural Network Analysis of NBI Endoscopy Data
The goal of this observational study is to accurate diagnose the stage of esophageal squamous cell carcinoma in order to help physicians to decide the appropriate clinical treatment.
- Trial name
- NCT06252974
- Volunteers
- 500 people
- Sponsor
- RenJi Hospital
Adenocarcinoma of the Esophagus, Adenocarcinomas of the Gastroesophageal Junction
Pralatrexate and Docetaxel in Treating Patients With Stage IV Esophageal or Gastroesophageal Cancer Who Have Failed Platinum-Based Therapy
RATIONALE: Pralatrexate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by…
- Conditions
- Adenocarcinoma of the Esophagus, Adenocarcinomas of the Gastroesophageal Junction, Recurrent Esophageal Cancer, Squamous Cell Carcinoma of the Esophagus
- Trial name
- NCT01129206
- Testing
- pralatrexate, docetaxel, fludeoxyglucose F 18
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Oral Squamous Cell Carcinoma (OSCC)
Case Review of Patients With Betel Nut-induced Oral Cancer Treated With Pembrolizumab and Cetuximab
Chart review of records of patients treated for betel nut-induced oral cancer with pembrolizumab and cetuximab.
- Trial name
- NCT07015333
- Testing
- pembrolizumab and cetuximab
- Where
- Northern Mariana Islands
- Volunteers
- 31 people
- Sponsor
- Commonwealth Healthcare Corporation
Head and Neck Cancer
Study of Blood and Tissue Samples From Patients With Larynx Cancer, Pharynx Cancer, or Oral Cavity Cancer
RATIONALE: Studying samples of blood and tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- CARIO (NCT00963326)
- Testing
- laboratory biomarker analysis
- Where
- 9 sites in France
- Volunteers
- 30 people
- Sponsor
- Centre Oscar Lambret
Radiation-Induced Skin Fibrosis, Head and Neck Squamous Cell Carcinoma
Clinical Study of CFH Protein Via Ice Microneedles for Radiation-Induced Skin Fibrosis
This phase I, open-label, single-arm, non-randomized clinical trial uses a "3+3" dose-escalation design to evaluate the safety, tolerability, and preliminary efficacy of intradermal delivery of complement factor H (CFH) fragment…
- Trial name
- NCT07567235
- Testing
- CFH Protein-loaded Ice Microneedles (0.5 mg), CFH Protein-loaded Ice Microneedles (1.0 mg), CFH Protein-loaded Ice Microneedles (2.0 mg)
- Where
- China
- Volunteers
- 9 people
- Sponsor
- West China Hospital
Cancer-Associated Anorexia, Head and Neck Squamous Cell Carcinoma
Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial
This phase II trial compares the effect of adding olanzapine to standard of care symptom management for nausea to standard of care alone in managing an abnormal loss of the appetite for food (anorexia) in patients treated with…
- Conditions
- Cancer-Associated Anorexia, Head and Neck Squamous Cell Carcinoma, Neck Squamous Cell Carcinoma of Unknown Primary
- Trial name
- NCT06995508
- Testing
- Best Practice, Olanzapine, Questionnaire Administration
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Roswell Park Cancer Institute
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma
Lymph Node Mapping and Sentinel Lymph Node Identification in Patients With Stage IB1 Cervical Cancer
This clinical trial is studying how well lymph node mapping and sentinel lymph node identification work in finding lymph node metastases in patients with stage IB1 cervical cancer.
- Conditions
- Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Stage I Cervical Cancer
- Trial name
- NCT00070317
- Testing
- Isosulfan Blue, Lymph Node Mapping, Lymphangiography
- Where
- United States
- Volunteers
- 102 people
- Sponsor
- Gynecologic Oncology Group
Head and Neck Cancer
Intensity-Modulated Radiation Therapy, Pemetrexed, and Erlotinib in Treating Patients With Recurrent or Second Primary Head and Neck Cancer
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Trial name
- NCT00573989
- Testing
- erlotinib hydrochloride, pemetrexed disodium, quality-of-life assessment
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Wake Forest University Health Sciences
Esophageal Squamous Cell Carcinoma
Neoadjuvant Chemoimmunotherapy Followed by Surgery and Postoperative Radioimmunotherapy
The goal of this study was to explore the efficacy and safety of neoadjuvant chemoimmunotherapy followed by surgery and postoperative radioimmunotherapy in patients with locally advanced esophageal squamous cell carcinoma
- Trial name
- NCT06602843
- Testing
- Neoadjuvant chemoimmunotherapy followed by surgery and postoperative radioimmunotherapy
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Anhui Provincial Hospital
Esophageal Squamous Cell Carcinoma
A Translational Study of Tumor Antigen-pulsed DC Vaccine for ESCC
The aim of this single center, single arm and prospective study is to explore the safety and efficacy of tumor antigen-pulsed DC vaccine( OCDC and NeoDC) for postoperative adjuvant treatment of ESCC
- Trial name
- NCT05317325
- Testing
- OCDC vaccine; NeoDC vaccine
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Sichuan University
Esophageal Squamous Cell Carcinoma
Efficacy and Safety of Adebrelimab Combined With Chemoradiotherapy in Patients With Unresectable Locally Advanced or Postoperative Recurrent Esophageal Squamous Cell Carcinoma
This study was a multi-center, single-arm, open-label phase II clinical trial. Thirty patients with unresectable locally advanced or postoperative recurrent esophageal squamous cell carcinoma were treated with concurrent…
- Trial name
- NCT06885814
- Testing
- Adebrelimab: 1200 mg day1, Q3W, 3 times
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Non Small Cell Lung Cancer, Cancer of the Head and Neck
An Expanded Access Programme With Iressa for Patients With Non-Small-Cell Lung Cancer and Cancer of the Head and Neck
The purpose of this study is to provide ZD1839 for those patients with locally advanced and/or metastatic non-operable non-small cell lung cancer (stage III or IV) or recurrent and/or metastatic squamous cell head and neck cancer…
- Trial name
- NCT00684385
- Testing
- ZD1839
- Where
- 34 sites in Germany, Hungary and 2 more
- Sponsor
- AstraZeneca
Head and Neck Cancer Squamous Cell Carcinoma, ELDERLY PEOPLE
Hypofractionated Radiotherapy for HNSCC in Elderly Patients
Head and neck squamous cell carcinoma (HNSCC) is a common malignant tumor, with 25% of HNSCC patients diagnosed at over 70 years of age. As the population ages, it is expected that by 2030, this proportion will exceed 60%.
- Conditions
- Head and Neck Cancer Squamous Cell Carcinoma, ELDERLY PEOPLE, Hypofractionation
- Trial name
- HNSCC (NCT06768125)
- Testing
- Hypofractionated Radiation Therapy
- Where
- China
- Volunteers
- 51 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Locally Advanced Esophageal Squamous Cell Carcinoma
A Feasibility Trial of Nivolumab With Neoadjuvant CF or DCF Therapy for Locally Advanced Esophageal Carcinoma
The main purpose of this study is to evaluate the safety of the neoadjuvant therapy, nivolumab with CF (5-FU, CDDP) or nivolumab with DCF (5-FU, CDDP, DTX), for locally advanced esophageal carcinoma.
- Trial name
- NCT03914443
- Testing
- Nivolumab, 5-FU, CDDP
- Where
- Japan
- Volunteers
- 37 people
- Sponsor
- National Cancer Center, Japan
Esophageal Squamous Cell Carcinoma (ESCC)
A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
The purpose of this study was to evaluate the efficacy and safety of tislelizumab as second line treatment in participants with advanced unresectable/metastatic ESCC that had progressed during or after first line therapy.
- Trial name
- NCT03430843
- Testing
- Tislelizumab, Paclitaxel, Docetaxel
- Where
- 104 sites in United States, Belgium and 9 more
- Volunteers
- 512 people
- Sponsor
- BeiGene
Esophageal Squamous Cell Carcinoma
NCI UNC Project ESCC
Background: Esophageal cancer is a common cause of cancer deaths. Most cases of this cancer are esophageal squamous cell carcinoma (ESCC). Many of these cases come from two parts of the world with high-risk.
- Trial name
- NCT03206125
- Where
- 2 sites in Malawi
- Volunteers
- 648 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Digital PET Scan for the Prediction of Outcomes in Patients With Locally Advanced Oropharyngeal Cancer
This trial studies how well digital PET scan works in predicting outcomes in patients with oropharyngeal cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced).
- Conditions
- Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Locally Advanced Oropharyngeal Squamous Cell Carcinoma, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Trial name
- NCT04140513
- Testing
- Fludeoxyglucose F-18, Positron Emission Tomography
- Where
- United States
- Sponsor
- Ohio State University Comprehensive Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.